Cambridge-based Nuclera, a BioTech firm accelerating drug discovery by offering entry to practical proteins via its benchtop eProtein Discovery System, in the present day introduced a €10 million ($12 million) financing extension, bringing the Firm’s complete Sequence C funding to €74 million ($87 million).
The increase was led by Elevage Medical Applied sciences and Jonathan Milner, joined by current buyers British Enterprise Financial institution and GK Goh. The funding will speed up the combination of antibody expression and binding validation capabilities into the Firm’s eProtein Discovery benchtop system.
Dr Michael Chen, CEO and co-founder, Nuclera, says: “This financing underscores our rising momentum and demonstrates that we’re increasing eProtein Discovery into one of many fastest-growing segments of biologics R&D. Scientists more and more require scalable, high-quality datasets to energy AI fashions in biologics discovery. We’re positioning Nuclera to develop into a foundational platform for the way forward for protein and antibody engineering, in the end accelerating therapeutic discovery timelines.”
Alongside Nuclera’s Sequence C extension, sector evaluation from 2025 and 2026 factors to sustained investor curiosity in European BioTech platforms centered on protein engineering, biologics, and AI-enabled discovery.
In early 2026, Helsinki-based Avenue Biosciences raised €4.8 million to scale its protein engineering expertise aimed toward enhancing reliability in biologics manufacturing, reflecting demand for quicker and extra standardised protein manufacturing workflows.
On the bigger finish of the market, Munich-headquartered Tubulis secured a €308 million Sequence C to advance its antibody-drug conjugate platform, underlining sturdy capital allocation in direction of antibody-centric modalities. In Italy, Milan-based NanoPhoria Bioscience closed an €83.5 million Sequence A to progress its drug supply expertise, whereas London-based Latent Labs raised €47.9 million to develop a programmable biology platform integrating AI into organic engineering.
Taken collectively, these rounds symbolize greater than €440 million in disclosed funding. Inside this context, Nuclera’s expanded Sequence C locations it amongst a cohort of European firms constructing enabling infrastructure for next-generation biologics R&D, with a selected emphasis on scalable, high-quality protein and antibody knowledge to help AI-driven analysis.
Dr Michael Wasserman, Chief Working Officer, Elevage Medical Applied sciences, commented: “Since our preliminary funding, Nuclera has made significant progress in increasing the capabilities, adoption, and world attain of the eProtein Discovery platform. The extension of the system into full-format antibody expression, purification, and binding validation represents a major step ahead, notably as biologics discovery turns into more and more pushed by AI-enabled workflows that require scalable, high-quality datasets.
“Elevage is proud to proceed supporting Nuclera because it evolves right into a foundational platform for protein and antibody engineering, serving to researchers speed up discovery timelines and cut back friction throughout the drug growth course of.”
Based in 2013, Nuclera’s mission is to speed up discovery by offering researchers speedy, easy accessibility to the highest-quality practical proteins important for drug discovery analysis.
The Firm’s eProtein Discovery benchtop system combines distinctive cell-free expression techniques, novel digital microfluidics, and sturdy screening knowledge to empower scientists to carry out multiplex protein screening, characterization, and small-scale expression in-house.
By offering clear steerage on which protein has one of the best probability of success from the beginning, eProtein Discovery reportedly reduces the time, value, and uncertainty historically related to protein expression and purification.
The corporate says researchers can generate soluble, purified proteins, together with difficult membrane proteins, for downstream practical testing in beneath 48 hours, considerably accelerating workflows in contrast with months-long cell-based strategies.
Dr Jonathan Milner, Chairman of the Nuclera Board of Administrators, founder and former CEO of Abcam, Inc and CEO of Meltwind Advisory, added: “Nuclera is fixing one of the vital urgent bottlenecks in biologics discovery – the gradual, fragmented, and resource-intensive strategy of synthesising full-format antibodies. The staff’s success in membrane proteins, one of the vital difficult protein lessons, mixed with their microfluidic experience, locations them in a novel place to remodel antibody growth workflows.”
Increasing eProtein Discovery with antibody-specific capabilities represents a strategic step as Nuclera strikes into AI-enabled protein engineering, addressing a crucial business want for scalable, standardised, and high-quality datasets that can be utilized to energy next-generation AI fashions in biologics discovery.
The development will allow researchers to carry out end-to-end expression, purification, and binding validation of full-format antibodies on an built-in, high-throughput system.
Because the closure of its earlier Sequence C financing in 2024, the Firm has superior its eProtein Discovery capabilities with the addition of a membrane protein workflow, prolonged its world footprint to broaden buyer entry throughout APAC and the Center East, and initiated a collaboration with Cytiva to speed up the trail from DNA to totally purified and characterised proteins to raised perceive drug-target interactions.
In parallel, the eProtein Discovery system was put in at Domainex, the primary CRO implementation of the system, streamlining protein manufacturing companies and additional validating the system’s industrial and scientific impression.
